Related Experiment Video
Updated: Jan 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis
Wei Wang1, Zirui Dong2, Baoan Hong1
1Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing, P. R. China.
Background:
Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non-cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.
Objectives:
To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).
Methods:
AE reports related to ADT drugs were extracted from FAERS (Q1 2004-Q3 2024). Disproportionality analyses-including Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)-were conducted to identify significant cardiovascular safety signals.
Results:
Different ADT agents exhibited distinct cardiovascular AE profiles. Some drugs were linked to a broader range of CVD-related AEs, while others had more limited associations.
Conclusions:
ADT agents demonstrate heterogeneous cardiotoxicity profiles. These findings emphasize the need for individualized treatment strategies, particularly in patients with pre-existing CVD risks, and may aid clinicians in balancing cancer control with cardiovascular safety.
Related Concept Videos
Cancer Survival Analysis
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Treatment Resistant Cancers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Therapeutic Drug Monitoring: Affecting Factors
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

